Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections
Prosthetic Joint Infection, Prosthetic Infection, Hip Prosthesis Infection
About this trial
This is an interventional diagnostic trial for Prosthetic Joint Infection focused on measuring staphylococci, biofilm, antimicrobial resistance, periprosthetic infection
Eligibility Criteria
Inclusion Criteria:
- first PJI in hip or knee according to Musculoskeletal Infection Society (MSIS) definitions
- first DAIR
- mono-microbial staphylococcal infection
- 14 days of intravenous treatment with either cloxacillin or vancomycin
- standardized administration of local antibiotics
Exclusion Criteria:
- allergy/previous toxic event/unacceptable drug interaction to most effective antibiotic combination according to either MIC or MBEC
- severe drug interactions to MBEC-guided compound
Sites / Locations
- Ortopedi, Sahlgrenska University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
MBEC and MIC susceptibility testing
MIC susceptibility testing
For all administered antimicrobials staphylococcal strains must be susceptible in disc diffusion tests/MIC, regardless of MBEC-level. Antibiotic combinations will be selected from 5 already recommended non-cell wall active anti-staphylococcal antibiotics with high per-oral bio-availabilities and acceptable bone penetration used in the treatment of PJIs: rifampicin, fusidic acid, ciprofloxacin/levofloxacin and clindamycin. MBEC cut-off for replacement with 2nd or 3rd line antibiotic: RIF MBEC/MIC > 8; LEV MBEC/MIC > 5; FUS MBEC/MIC > 3; CLI MBEC/MIC > 4; LIN MBEC/MIC > 2; T/S MBEC > MIC Second line of treatment: RIF and Fusidic acid 500 mg TID (ter in die) RIF and Clindamycin 450 - 600 mg TID LEV and Fusidic acid 500 mg TID LEV and Clindamycin 450 mg TID Third line of treatment: Linezolid 600 mg BID (bis in die) Sulfamethoxazole/Trimethoprim 800/160 mg TID Clindamycin 450 mg TID and Fusidic acid 500 mg TID
If the causative bacterium is susceptible according to MIC diagnostics, the patient will follow the first line of treatment: Rifampicin 750-900 mg/day + Levofloxacin 750 mg BID